IBRX – ImmunityBio, Inc.
Float Short %
40.89
Margin Of Safety %
Put/Call OI Ratio
0.39
EPS Next Q Diff
-0.01
EPS Last/This Y
0.19
EPS This/Next Y
0.15
Price
8.7
Target Price
11.8
Analyst Recom
1
Performance Q
314.29
Upside
-269.0%
Beta
-0.13
Ticker: IBRX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | IBRX | 6.45 | 0.29 | 0.59 | 480553 |
| 2026-01-26 | IBRX | 6.21 | 0.33 | 0.95 | 508763 |
| 2026-01-27 | IBRX | 5.98 | 0.32 | 0.26 | 513955 |
| 2026-01-28 | IBRX | 6.16 | 0.33 | 0.33 | 523663 |
| 2026-01-29 | IBRX | 5.93 | 0.33 | 0.31 | 538992 |
| 2026-01-30 | IBRX | 6.26 | 0.33 | 0.20 | 544253 |
| 2026-02-02 | IBRX | 6.12 | 0.33 | 0.61 | 553951 |
| 2026-02-03 | IBRX | 6.34 | 0.33 | 0.39 | 556859 |
| 2026-02-04 | IBRX | 5.88 | 0.32 | 0.37 | 560538 |
| 2026-02-05 | IBRX | 5.64 | 0.33 | 0.06 | 564947 |
| 2026-02-06 | IBRX | 6.04 | 0.33 | 0.26 | 570301 |
| 2026-02-09 | IBRX | 6.93 | 0.33 | 0.21 | 573776 |
| 2026-02-10 | IBRX | 6.57 | 0.32 | 0.07 | 582827 |
| 2026-02-11 | IBRX | 6.53 | 0.32 | 0.10 | 590346 |
| 2026-02-12 | IBRX | 6.62 | 0.32 | 0.27 | 600147 |
| 2026-02-13 | IBRX | 5.99 | 0.32 | 0.21 | 601744 |
| 2026-02-17 | IBRX | 6.01 | 0.32 | 0.29 | 622141 |
| 2026-02-18 | IBRX | 8.54 | 0.33 | 0.23 | 631713 |
| 2026-02-19 | IBRX | 8.6 | 0.35 | 0.35 | 657829 |
| 2026-02-20 | IBRX | 8.79 | 0.39 | 0.06 | 674745 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | IBRX | 6.51 | -20.8 | 72.9 | -0.40 |
| 2026-01-26 | IBRX | 6.20 | -20.8 | 58.6 | -0.40 |
| 2026-01-27 | IBRX | 5.97 | -20.8 | 58.9 | -0.40 |
| 2026-01-28 | IBRX | 6.16 | -20.8 | 44.6 | -0.40 |
| 2026-01-29 | IBRX | 5.93 | -20.8 | 59.0 | -0.40 |
| 2026-01-30 | IBRX | 6.27 | -20.8 | 41.4 | -0.40 |
| 2026-02-02 | IBRX | 6.13 | -20.8 | 55.9 | -0.40 |
| 2026-02-03 | IBRX | 6.35 | -20.8 | 45.6 | -0.40 |
| 2026-02-04 | IBRX | 5.87 | -20.8 | 66.3 | -0.40 |
| 2026-02-05 | IBRX | 5.64 | -20.8 | 59.9 | -0.40 |
| 2026-02-06 | IBRX | 6.04 | -20.8 | 38.9 | -0.40 |
| 2026-02-09 | IBRX | 6.97 | -20.8 | 24.0 | -0.40 |
| 2026-02-10 | IBRX | 6.56 | -20.8 | 63.4 | -0.40 |
| 2026-02-11 | IBRX | 6.52 | -20.8 | 53.4 | -0.40 |
| 2026-02-12 | IBRX | 6.62 | -20.8 | 49.6 | -0.40 |
| 2026-02-13 | IBRX | 5.95 | -20.8 | 71.3 | -0.40 |
| 2026-02-17 | IBRX | 6.01 | -20.8 | 50.1 | -0.40 |
| 2026-02-18 | IBRX | 8.54 | -20.8 | -26.3 | -0.40 |
| 2026-02-19 | IBRX | 8.54 | -20.8 | - | -0.40 |
| 2026-02-20 | IBRX | 8.70 | -20.8 | - | -0.40 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | IBRX | -0.03 | 5.89 | 36.48 |
| 2026-01-26 | IBRX | -0.03 | 5.91 | 36.46 |
| 2026-01-27 | IBRX | -0.03 | 5.91 | 36.46 |
| 2026-01-28 | IBRX | -0.03 | 5.91 | 38.38 |
| 2026-01-29 | IBRX | -0.03 | 5.91 | 38.38 |
| 2026-01-30 | IBRX | -0.03 | 5.91 | 38.38 |
| 2026-02-02 | IBRX | -0.03 | 5.93 | 38.38 |
| 2026-02-03 | IBRX | -0.03 | 5.93 | 38.38 |
| 2026-02-04 | IBRX | -0.03 | 5.93 | 38.38 |
| 2026-02-05 | IBRX | -0.03 | 5.93 | 38.38 |
| 2026-02-06 | IBRX | -0.03 | 5.93 | 38.38 |
| 2026-02-09 | IBRX | -0.03 | 5.45 | 38.38 |
| 2026-02-10 | IBRX | -0.03 | 5.45 | 38.38 |
| 2026-02-11 | IBRX | -0.03 | 5.45 | 40.85 |
| 2026-02-12 | IBRX | -0.03 | 5.45 | 40.85 |
| 2026-02-13 | IBRX | -0.03 | 5.45 | 40.85 |
| 2026-02-17 | IBRX | -0.03 | 9.14 | 40.85 |
| 2026-02-18 | IBRX | -0.03 | 9.14 | 40.89 |
| 2026-02-19 | IBRX | -0.03 | 9.14 | 40.89 |
| 2026-02-20 | IBRX | -0.03 | 9.14 | 40.89 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.07
Avg. EPS Est. Current Quarter
-0.1
Avg. EPS Est. Next Quarter
-0.07
Insider Transactions
-0.03
Institutional Transactions
9.14
Beta
-0.13
Average Sales Estimate Current Quarter
35
Average Sales Estimate Next Quarter
44
Fair Value
Quality Score
23
Growth Score
39
Sentiment Score
99
Actual DrawDown %
78.7
Max Drawdown 5-Year %
Target Price
11.8
P/E
Forward P/E
PEG
P/S
103.79
P/B
P/Free Cash Flow
EPS
-0.42
Average EPS Est. Cur. Y
-0.4
EPS Next Y. (Est.)
-0.26
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-422.28
Relative Volume
1.54
Return on Equity vs Sector %
37.5
Return on Equity vs Industry %
54.9
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
ImmunityBio, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 673
ImmunityBio, Inc., a commercial stage biotechnology company, develops next-generation therapies that bolster the natural immune systems to defeat cancers and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeiGene, Ltd. ImmunityBio, Inc. is based in San Diego, California.
stock quote shares IBRX – ImmunityBio, Inc. Stock Price stock today
news today IBRX – ImmunityBio, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch IBRX – ImmunityBio, Inc. yahoo finance google finance
stock history IBRX – ImmunityBio, Inc. invest stock market
stock prices IBRX premarket after hours
ticker IBRX fair value insiders trading